Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12

Tumor Biology

Volumn 30, Issue 2, 2009, Pages 100-107

  Korbakis, Dimitrios ^a   Scorilas, Andreas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

5 Fluorouracil; AGS cells; Apoptosis; Bcl 2; BCL2 family; BCL2L12; Irinotecan; Leucovorin

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; COMPLEMENTARY DNA; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL 2 L12; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL2L12 PROTEIN, HUMAN; CAMPTOTHECIN; DRUG DERIVATIVE; MUSCLE PROTEIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; GAPDH GENE; GENE EXPRESSION REGULATION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION; RNA EXTRACTION; STOMACH CANCER; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CAMPTOTHECIN; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; FLUOROURACIL; GENE EXPRESSION; HUMANS; LEUCOVORIN; MUSCLE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; STOMACH NEOPLASMS;

EID: 65549112656     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218160     Document Type: Article

References (42)

1. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L: Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized italian trial. Italian gastrointestinal tumor study group. Ann Surg 1999; 230:170-178.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
3. Ebert MP, Rocken C: Molecular screening of gastric cancer by proteome analysis. Eur J Gastroenterol Hepatol 2006; 18 : 847-853.
4. Thomadaki H, Scorilas A: Bcl2 family of apoptosis-related genes: Functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006; 43:1-67.
5. Adams JM, Cory S: The bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
6. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM: Bax-independent inhibition of apoptosis by Bcl-XL. Nature 1996; 379:554-556.
7. Gross A, McDonnell JM, Korsmeyer SJ: Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13:1899-1911.
8. Yin XM, Oltvai ZN, Korsmeyer SJ: BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994; 369: 321-323.
9. Kirkin V, Joos S, Zornig M: The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004; 1644:229-249.
10. Scorilas A, Kyriakopoulou L, Yousef GM, Ashworth LK, Kwamie A, Diamandis EP: Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the BCL-2 family. Genomics 20 01; 72: 217-2 21 .
11. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
12. Katsumata M, Siegel RM, Louie DC, Miya-shita T, Tsujimoto Y, Nowell PC, Greene MI, Reed JC: Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci USA 1992; 89:11376-11380.
13. Binder C, Marx D, Overhoff R, Binder L, Schauer A, Hiddemann W: Bcl-2 protein expression in breast cancer in relation to estab-lished prognostic factors and other clinico-pathological variables. Ann Oncol 1995; 6: 1005-1010.
14. Flohil CC, Janssen PA, Bosman FT: Expression of Bcl-2 protein in hyperplastic polyps, adenomas, and carcinomas of the colon. J Pathol 1996; 178: 393 -397.
15. Laudanski J, Chyczewski L, Niklinska WE, Kretowska M, Furman M, Sawicki B, Niklin-ski J: Expression of Bcl-2 protein in non-small cell lung cancer: Correlation with clin-icopathology and patient survival. Neo-plasma 1999; 46: 25-30.
16. Ramsay JA, From L, Kahn HJ: Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol 1995; 8: 150 -154.
17. Tsuji M, Murakami Y, Kanayama H, Sano T, Kagawa S: Immunohistochemical analysis of Ki-67 antigen and Bcl-2 protein expression in prostate cancer: effect of neoadjuvant hormonal therapy. Br J Urol 1998; 81 : 116 -1 21.
18. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilac-qua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 10 0 3 -10 0 7.
19. Kamesaki S, Kamesaki H, Jorgensen TJ, Ta-nizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
20. Schorr K, Li M, Krajewski S, Reed JC, Furth PA: Bcl-2 gene family and related proteins in mammary gland involution and breast cancer. J Mammary Gland Biol Neoplasia 1999; 4:153-164.
21. Bairey O, Zimra Y, Shaklai M, Okon E, Rabi-zadeh E: Bcl-2, Bcl-X, Bax, and Bak expression in short- and long-lived patients with diffuse large b-cell lymphomas. Clin Cancer Res 1999; 5: 2860-2866.
22. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archim baud E, Magaud JP, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81:3091-3096.
23. Karakas T, Maurer U, Weidmann E, Mie-thing CC, Hoelzer D, Bergmann L: High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol 1998; 9:159-165.
24. Thomadaki H, Scorilas A: Molecular profile of the BCL2 family of the apoptosis related genes in breast cancer cells after treatment with cytotoxic/cytostatic drugs. Connect Tissue Res 2008; 49: 261-264.
25. Floros KV, Talieri M, Scorilas A: Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem 2006; 387:1629-1633.
26. Floros KV, Thomadaki H, Katsaros N, Talieri M, Scorilas A: Mrna expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubi-cin. Biol Chem 2004; 385:1099-1103.
27. Gil J, Yamamoto H, Zapata JM, Reed JC, Perucho M: Impairment of the proapoptotic activity of Bax by missense mutations found in gastrointestinal cancers. Cancer Res 1999; 59:2034-2037.
28. Floros KV, Thomadaki H, Florou D, Talieri M, Scorilas A: Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide. Ann NY Acad Sci 2006; 1090:89- 97.
29. Tong QS, Zheng LD, Wang L, Liu J, Qian W: Bak overexpression mediates p53-indepen-dent apoptosis inducing effects on human gastric cancer cells. BMC Cancer 2004; 4: 33.
30. Kondo S, Shinomura Y, Miyazaki Y, Kiyo-hara T, Tsutsui S, Kitamura S, Nagasawa Y, Nakahara M, Kanayama S, Matsuzawa Y: Mutations of the Bak gene in human gastric and colorectal cancers. Cancer Res 2000; 60: 4328-4330.
31. Lee HW, Lee SS, Lee SJ, Um HD: Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res 2003; 63:1093-1100.
32. Choi SS, Park IC, Yun JW, Sung YC, Hong SI, Shin HS: A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow. Oncogene 1995; 11:1693-1698.
33. Pang XP, Hershman JM, Karsan A: TNF-α induction of A1 expression in human cancer cells. Oncol Res 1997; 9:623-627.
34. Krajewska M, Kitada S, Winter JN, Variako-jis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, Meinhold-Heerlein I, Duffy MJ, Schimmer AD, Tsao M, Brown E, Sawyers A, Andreeff M, Mercola D, Krajewski S, Reed JC: Bcl-B expression in human epithelial and nonepi-thelial malignancies. Clin Cancer Res 2008; 14: 3011-3021.
35. Mathioudaki K, Scorilas A, Papadokosto-poulou A, Xynopoulos D, Arnogianaki N, Agnanti N, Talieri M: Expression analysis of BCL2L12, a new member of apoptosis-relat-ed genes, in colon cancer. Biol Chem 2004; 385: 779-783.
36. Talieri M, Diamandis EP, Katsaros N, Gour-giotis D, Scorilas A: Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors. Thromb Haemost 2003; 89: 1081-1088.
37. Thomadaki H, Talieri M, Scorilas A: Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer. Cancer Lett 2007; 247:48-55.
38. Floros KV, Thomadaki H, Lallas G, Katsaros N, Talieri M, Scorilas A: Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12. Ann NY Acad Sci 2003; 1010:153-158.
39. Thomadaki H, Talieri M, Scorilas A: Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS. Biol Chem 2006; 387: 1081-1086.
40. Thomadaki H, Scorilas A: Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12. Ann NY Acad Sci 2007; 1095:35-44.
41. Uhlmann EJ, Subramanian T, Vater CA, Lutz R, Chinnadurai G: A potent cell death activity associated with transient high level expression of BCL-2. J Biol Chem 1998; 273: 17926-17932.
42. Wang NS, Unkila MT, Reineks EZ, Distel-horst CW: Transient expression of wild-type or mitochondrially targeted Bcl-2 induces apoptosis, whereas transient expression of endoplasmic reticulum-targeted Bcl-2 is protective against Bax-induced cell death. J Biol Chem 2001; 276:44117-44128.